SCHEMBL4458292

SCHEMBL4458292

COC(=O)Nc1cccc(N(c2ccc(F)cc2)C(c2cccnc2)c2cccnc2)n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
LMNA P02545 3/20 0.41
TP53 P04637 2/20 0.41
KCNA5 P22460 2/20 0.40
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
KCND3 Q9UK17 1/20 0.40
SCN9A Q15858 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
TSHR P16473 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
PKM P14618 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4456765 0.89 POLB (0.42) POLBLMNATP53KCNA5KCNE1
SCHEMBL4469178 0.88 POLB (0.41) POLBLMNATP53KCNA5KCNE1
SCHEMBL13971462 0.84 KCNA5 (0.38) POLBLMNATP53KCNA5KCNE1
SCHEMBL4457249 0.81 KCNA5 (0.61) POLBLMNAKCNA5KCNE1KCNQ1
SCHEMBL14435382 0.81 KCNA5 (0.39) POLBLMNATP53KCNA5KCNE1
SCHEMBL4461864 0.79 SMN1; SMN2 (0.38) LMNAKCNA5L3MBTL1TSHRPKM
SCHEMBL4472006 0.79 POLB (0.38) POLBLMNATP53KCNA5KCNE1
SCHEMBL4453052 0.78 ALDH1A1 (0.40) POLBALDH1A1
SCHEMBL4470641 0.78 POLB (0.37) POLBKCNA5KCNE1KCNQ1KCND3
SCHEMBL4453045 0.78 NR3C2 (0.39) TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP claimed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 POLB 4703/4885LMNA 904/4885TP53 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.